Clinical Trial Update: Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex [Phase 2]

View source ↗

Summary

Phase 2 long-term open-label study evaluating the safety of diacerein 1% ointment topical formulation in epidermolysis bullosa simplex.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Epidermolysis Bullosa Simplex

Drugs mentioned

• Diacerein 1% ointment (diacerein)

Snippet

Sponsor: Castle Creek Pharmaceuticals, LLC | Conditions: Epidermolysis Bullosa, Epidermolysis Bullosa Simplex | Phase 2 | Status: COMPLETED | Results posted: 2020-09-16